Leukemia Posts Page 2 on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

First-line treatment with ibrutinib – a review

Posted by on Mar 11, 2018 in Leukemia | 0 comments

In a nutshell This study outlined recent evidence on the use of ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL). Some background Tyrosine kinase inhibitor therapy is a type of immunotherapy that blocks signals needed for tumors to grow. This includes the Bruton tyrosine kinase inhibitor ibrutinib. Ibrutinib blocks a signal that keeps the...

Read More

17p deletion and 8q24 gain: Two chromosomal abnormalities that can predict outcomes

Posted by on Mar 11, 2018 in Leukemia | 0 comments

In a nutshell This study examined causes and outcomes of a chromosomal abnormality known as 17p deletion in chronic lymphocytic leukemia (CLL). Researchers reported poor outcomes for patients that have both 17p deletion and 8q24 gain. Some background Certain genetic changes in CLL can make it more difficult to treat. Changes in the chromosomes, such...

Read More

Rituximab, cladribine and cyclophosphamide: Early results of a new treatment combination with and without maintenance therapy

Posted by on Mar 11, 2018 in Leukemia | 0 comments

In a nutshell This study examined a new treatment combination known as RCC followed by rituximab (Rituxan) maintenance therapy for chronic lymphocytic leukemia (CLL). These results support the safety and effectiveness of RCC followed by rituximab maintenance therapy. Risk factors of disease progression were identified. Some background The chemotherapy...

Read More

Predicting ischemic heart disease and stroke in survivors of childhood cancer

Posted by on Mar 10, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the individual risk of ischemic heart disease and stroke through age 50 in 5-year survivors of childhood cancer. The authors concluded that these conditions can be reasonably predicted using information available after childhood cancer therapy. Some background For the 400,000 childhood cancer survivors in the...

Read More

Predicting ischemic heart disease and stroke in survivors of childhood cancer

Posted by on Mar 10, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the individual risk of ischemic heart disease and stroke through age 50 in 5-year survivors of childhood cancer. The authors concluded that these conditions can be reasonably predicted using information available after childhood cancer therapy. Some background For the 400,000 childhood cancer survivors in the...

Read More

Right To Try: Needed Legislation or Snake Oil?

Right To Try: Needed Legislation or Snake Oil?

Posted by on Mar 10, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 1 comment

Thirty-eight states in the US have passed “Right To Try” laws. These are laws that are created to give terminally ill patients who have run out of options access to experimental drugs that have not completed the FDA approval process.  There is an effort underway to pass this type of legislation on a federal level. On February 8, the #LCSM (Lung...

Read More

Stem cell transplants in older patients with acute lymphoblastic leukemia

Posted by on Mar 7, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcome for patients aged over 60 who underwent reduced intensity allogeneic stem cell transplant. This study concluded that a subset of these patients will have extended survival and disease-free state following treatment. Some background Hematopoietic stem cell transplantation (HSCT) is increasingly...

Read More

The prevalence of metabolic syndrome in survivors of childhood acute leukemia

Posted by on Mar 7, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the prevalence of metabolic syndrome in adult survivors of childhood acute leukemia. This study also aimed to determine the effect of different therapies on the occurrence of metabolic syndrome in these patients. This study concluded that metabolic syndrome is frequent among childhood AL survivors, regardless...

Read More

Stopping TKI therapy: An overview of evidence

Posted by on Feb 25, 2018 in Leukemia | 0 comments

In a nutshell This study reviewed evidence on the safety and effectiveness of stopping TKI therapy in patients with chronic myeloid leukemia (CML). Authors concluded that discontinuing TKI therapy is safe and effective in many patients with deep molecular response. Some background Tyrosine kinase inhibitors (TKIs) is a first-line treatment for...

Read More

Ibrutinib in combination with bendamustine and rituximab improves quality of life factors in patients with severe impairment

Posted by on Feb 24, 2018 in Leukemia | 0 comments

In a nutshell This study examined how treatment with ibrutinib (Imbruvica), rituximab (Rituxan), and bendamustine (Treanda) impacts quality of life in chronic lymphocytic leukemia (CLL) patients. Factors such as fatigue, physical functioning, and well-being were all improved among those patients with the lowest scores before treatment. Some background...

Read More